Plasmodium Falciparum Malaria Clinical Trial
Official title:
Targeting High-risk Populations With Enhanced Reactive Case Detection: a Study to Assess the Effectiveness and Feasibility for Reducing Plasmodium Falciparum and P. Vivax Malaria in Southern Lao Peoples Democratic Republic
This study assesses the effectiveness and feasibility of enhanced reactive case detection (RACD) targeting high-risk villages and forest workers for reducing Plasmodium falciparum and Plasmodium vivax transmission in southern Lao Peoples Democratic Republic. The authors hypothesize that enhanced community-based RACD will be more effective than standard of care case management and RACD at reducing P. falciparum and P. vivax confirmed case incidence and parasite prevalence over an 18-month period in Lao Peoples Democratic Republic.
In the Greater Mekong Subregion (GMS), the risk of malaria infection is often due not to village-based transmission but rather to occupational and behavioral risk factors leading to exposure in forest settings. Additionally, a substantial portion of infections are asymptomatic and/or submicroscopic, limiting the scope of current diagnostics and surveillance approaches. The proposed research will evaluate the effectiveness of reactive case detection (RACD) using highly-sensitive rapid diagnostic tests (HS-RDTs), targeting both village and forest working populations, compared to control for reducing the health center catchment-level incidence and prevalence of P. falciparum and P. vivax within two provinces in Lao People's Democratic Republic. To test this hypothesis, this study will employ a cluster randomized controlled trial design with two comparison arms: (1) Control: standard of care - passive case management provided through community-based Village Malaria Workers (VMWs) and existing health facilities; includes village-based RACD with conventional rapid diagnostic tests (RDTs) conducted by district surveillance teams and (2) enhanced community-based RACD: RACD conducted by community-based VMWs using both HS-RDTs and conventional RDTs within villages and among forest workers. The primary outcome measures to assess effectiveness include P. falciparum and P. vivax confirmed case incidence over the study period; PCR-based P. falciparum and P. vivax prevalence at end line; and HS-RDT test positivity rate in village and forest worker RACD. Secondary outcomes measures will examine the operational feasibility, safety, and acceptability of VMW-led reactive approaches and glucose-6-phosphate dehydrogenase (G6PD) testing, referral to district or provincial-level facilities, safety and treatment adherence for P. vivax cases. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04577066 -
Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.
|
Phase 1/Phase 2 | |
Completed |
NCT01883609 -
A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S
|
Phase 1/Phase 2 | |
Completed |
NCT00593398 -
Malarial Immunity in Pregnant Cameroonian Women
|
||
Completed |
NCT01659281 -
Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand
|
N/A | |
Completed |
NCT00074841 -
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
|
Phase 2/Phase 3 | |
Completed |
NCT00314899 -
Fetal Immunity to Falciparum Malaria
|
||
Completed |
NCT02867059 -
SJ733 Induced Blood Stage Malaria Challenge Study
|
Phase 1 | |
Completed |
NCT00701961 -
Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy
|
Phase 2/Phase 3 | |
Completed |
NCT00338520 -
Hyperphenylalaninemia in Cerebral Malaria
|
N/A | |
Completed |
NCT00707200 -
The Cytoadherence in Pediatric Malaria (CPM) Study
|
N/A | |
Completed |
NCT00393757 -
Malaria Transmission and Immunity in Highland Kenya
|
||
Completed |
NCT03783299 -
Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic
|
Phase 4 | |
Completed |
NCT02614404 -
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
|
Phase 1 | |
Completed |
NCT00358332 -
Phase I Pediatric FMP2.1/AS02A Trial in Mali
|
Phase 1 | |
Completed |
NCT00730782 -
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
|
Phase 1 | |
Completed |
NCT00349713 -
FMP2.1 Trial in Bandiagara, Mali
|
Phase 1 | |
Recruiting |
NCT05052502 -
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
|
N/A | |
Completed |
NCT04093765 -
Mass Screening and Treatment for Reduction of Falciparum Malaria
|
N/A | |
Completed |
NCT03764527 -
Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar
|
Phase 4 | |
Completed |
NCT03773536 -
Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar
|
Phase 4 |